Anavex Life Sciences Corp (AVXL)

[MD investor]

The 50mg dose was a clearly defined endpoint to the trial. This is not cherry picking. In fact, this combination of 30 and 50 mg was destined to be comparable to historic untreated placebo Alzheimer’s data. Why it worked on cognition in this trial is anyone’s guess but good of course. The only issue why anavex 2-73 did not work by historic comparison was the theory of under dosing leading to low blood levels and leading to underperforming. The question is what happened to the 50mg people. Also who should be included? Since up titration was allowed, do you use intention to treat or the 50mg group and combine with the up titrated to 50mg group?
They need to compare 2 groups. The placebo group without sigma1 mutations to 50mg 2-73 combined groups without mutations. And make sure to see if aricept effected the results by a multiple regression analysis. And SOON!!